Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial

PURPOSE: Stereotactic body radiotherapy (SBRT) may have significant immunomodulatory effects that enhance tumor response to immune checkpoint inhibitors. This phase 2 clinical trial was conducted to evaluate the safety and efficacy of combining palliative SBRT with camrelizumab (an anti-PD1 monoclon...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jian-Xu, Su, Ting-Shi, Gong, Wen-Feng, Zhong, Jian-Hong, Yan, Liu-Ying, Zhang, Jie, Li, Li-Qing, He, Mei-Ling, Zhang, Rui-Jun, Du, You-Qin, Wang, Xiao-Ting, Liang, Shi-Xiong, Xiang, Bang-De
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525355/
https://www.ncbi.nlm.nih.gov/pubmed/36001228
http://dx.doi.org/10.1007/s12072-022-10396-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525355/
https://www.ncbi.nlm.nih.gov/pubmed/36001228
http://dx.doi.org/10.1007/s12072-022-10396-7

Ejemplares similares